With remarkable advances in gene sequencing, oncologists have focused attention on precision medicine, and specific gene mutations are now considered biomarkers or therapeutic targets (e.g., EGFR mutations in non-small-cell lung cancer and Gefitinib) (Nan et al., 2017). Here, EGFR is linked to non-small cell lung carcinoma.